Zoetis: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Nov. 5, 2026, Zoetis (NYSE:ZTS) reported a 1% revenue decline, excluding currency and acquisition effects. Lower veterinary clinic visits and generic competition continue to pressure pet care returns. Three things management said stand out.

1. Targeted Commercial Promotions Slow Dermatology Share Loss

Companion animal revenue fell 5% as lower veterinary visits and stiff competition hurt the core dermatology portfolio. Management deployed gross-to-net promotional investments, which reduce gross sales to net revenue through targeted customer discounts, to defend key vet accounts against rival drugs.

The promotional defense on derm managed to slow U.S. dermatology share loss in the quarter to 4 points in Q3.
-- Kristin Peck, Chief Executive Officer

2. Global Livestock Growth Helps Offset Pet Care Weakness

Livestock revenue grew 7% globally to $797 million, driven by demand for cattle treatments and poultry vaccines. This steady demand for agricultural protein balances cyclical drops in discretionary pet care spending across North America and Europe.

In contrast, livestock is benefiting from growing demand for quality protein sources. We're also seeing growing demand on animal health to improve productivity, support food security, and adopt a One Health approach.
-- Kristin Peck, Chief Executive Officer

3. Fast Lifecycle Approvals Extend Core Product Franchises

Management relies on lifecycle innovation, which develops new formulations or delivery methods for existing drugs, to protect mature product lines. Early approvals for Convenia RTU (a ready-to-use injectable antibiotic) and Simparica Duo (a parasiticide treating fleas, ticks, and worms) expand market reach ahead of schedule.

We also now expect approval of Simparica Duo by year-end, ahead of our original timeline, broadening the portfolio and extending access to customers with unmet needs.
-- Kristin Peck, Chief Executive Officer

Looking Ahead

Soft clinic traffic and pricing pressures are lingering into 2027, requiring tight operating cost control and targeted R&D (research and development) investments across core franchises. Zoetis relies on its global manufacturing scale, diagnostic platform growth, and multi-species reach to preserve cash flow while funding pipeline milestones.

As we approach 2027, we are going to be conservative or prudent as we put together our numbers. We have seen some macro trends over the last several quarters. We are not going to assume a market change in macro factors.
-- Jay Saccaro, Chief Financial Officer and Chief Operating Officer

The long-term thesis depends on converting lifecycle line extensions into durable market share while commercializing new therapeutic categories across renal disease, cardiology, and oncology.

Our market leadership was built on innovation. Sustaining it means extending the franchises we have today while building the capabilities that will enable the future of animal health.
-- Kristin Peck, Chief Executive Officer

The Motley Fool has positions in and recommends Zoetis. The Motley Fool has a disclosure policy.